NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.18 · Revenue $132.52M · 1 analysts
Est. EPS $-0.60 · Revenue $178.62M · 1 analysts
Est. EPS $-0.74 · Revenue $0.00 · 1 analysts
Est. EPS $-0.66 · Revenue $0.00 · 1 analysts
EPS $-2.16 · Revenue $0.00
EPS $-10.50 · Revenue $0.00
EPS $-26.30 · Revenue $0.00
EPS $-1.94 · Revenue $0.00
EPS $-3.20 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-8.3M | -319.0% | +295.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-2.8M | +35.1% | +99.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 4.9% | — | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.76x | -71.8% | -72.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $11.4M | +412.5% | +163.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.16 vs -180.00 | +98.8% | — | — |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Samuel Olivier | director | Warrant (right to buy) | A | 114,545 | $3.02 |
| Apr 27, 2026 | Samuel Olivier | director | Common Shares, par value CHF 0.05 per share | A | 81,818 | $2.75 |
| Apr 27, 2026 | Revel Michel | director, 10 percent owner, officer: CSO and Director | Common Shares, par value CHF 0.05 per share | A | 54,545 | $2.75 |
| Apr 27, 2026 | Revel Michel | director, 10 percent owner, officer: CSO and Director | Warrant (right to buy) | A | 76,363 | $3.02 |
| Mar 18, 2026 | Molakandov Kfir | officer: VP of R&D | Option to Purchase Ordinary Shares | — | 11,396 | $7.62 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Yossi Ben-Yossef | Honorary President & Strategic Consultant | USD 1,140,000 | Male | 1957 | Active |
Alexander Zwyer | Chief Business Officer & Executive Director | USD 557,000 | Male | 1969 | Active |
Ronen Twito | Chief Executive Officer & Executive Chairman | USD 356,000 | Male | 1975 | Active |
Eric Konofal | Head of Doxa Program | USD 122,000 | Male | 1967 | Active |
Omri Hagai | Chief Financial Officer | USD 14,000 | Male | 1986 | Active |
Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director | USD 4,000 | — | 1938 | Active |
Ariel Revel | Director of Medical Affairs | — | — | 1961 | Active |
Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN).
